News 05.04.19

A cup of coffee with….Lonneke Meijerink (Pivot Park)

Since March Lonneke started working at the Pivot Park Site Organisation as financial accountant. “After studying Business Economics at Tilburg...

Read more
News 01.04.19

Phio and Glycostem to Collaborate on Use of its sd-rxRNA® platform and Glycostem’s oNKord® Cell Therapy Products for the Next Generation of Natural Killer Cell-based Immunotherapy for Cancer Treatment

Phio Pharmaceuticals Corp. (NASDAQ: PHIO) announced today that it has entered into a research collaboration with Glycostem Therapeutics BV to explore the potential synergies of using Phio's self-delivering RNAi technology (sd-rxRNA®) in combination with Glycostem's proprietary Natural Killer-cell (NK-cell) generation technology (oNKord®) to develop cellular immunotherapies for cancer treatment with enhanced efficacy and/or safety.

Read more
News 29.03.19

Pharming announces a provisional commitment to invest in a minority stake in its fill & finish partner BioConnection BV

Pharming Group N.V. announces that it has made a provisional commitment to invest up to €1.6 million in cash and...

Read more
News 28.03.19

NTRC and Radboud explore new methods to predict chemotherapy response in ovarian cancer

NTRC and Radboudumc Nijmegen (The Netherlands) are developing a platform to predict the response of high-grade serous ovarian cancer patients to chemotherapy by using tumor and immune cells isolated at diagnosis. While patients receive normal standard-of-care treatment, data are collected to improve future diagnostics and care.

Read more
News 25.03.19

Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis

Sanofi, Lead Pharma’s collaborative partner in the development of SAR441169, successfully initiated first human dosing with this novel RORγt Inverse Agonist...

Read more
News 20.03.19

Effective discovery of synergistic combinations by in silico prioritization

uccessful cancer therapies are often based on drug combinations to halt cancer growth and prevent resistance mechanisms. A good way to find novel, unexpected synergistic drug combinations is unbiased high throughput screening on cancer cell lines, such as the NTRC SynergyScreen™ platform.

Read more
News 14.03.19

BioConnection further strengthens its position in the (bio) pharmaceutical CMO business by adding a Flexible GMP area to its current capabilities.

BioConnection opens this month, after an intensive engineering and validation program its Flexible GMP area. The area consists of several...

Read more
News 26.02.19

CEO Monique van Scherpenzeel – “I love to get my hands dirty in the lab”

Monique van Scherpenzeel (1981) exchanged the University for the Business world. In April 2018 she started her own company, GlycoMScan,...

Read more
News 19.02.19

A cup of coffee with…. Inez de Greef (3D-PharmXchange)

Inez de Greef, co-owner and founder of 3D-PharmXchange, started the company together with Ronald van der Geest because they find the development of medicines a fascinating field of expertise. “And not only do we find the field interesting, we also find it just as motivating to be able to share our knowledge with our team and apply it to customers.”

Read more